Bedtime THC: Normal Resting Measurements Did Not Exclude a Morning Tilt Response

Normal resting cardiovascular measurements the morning after THC do not establish a normal response to standing-related stress. An exploratory study found selected differences during head-up tilt, particularly among participants without regular cannabis use.

Rest and challenge were different endpoints

Adults with and without regular cannabis use underwent morning cardiovascular testing after placebo and bedtime oral THC. Measurements included heart rate, blood pressure and heart-rate variability during rest, tilt and recovery.

This was a physiological challenge study, rather than a driving assessment or a test of every cause of fainting. A resting reading and a response to a change in posture answer different questions.

The significant finding was selective

A group-by-treatment-by-time interaction was significant for diastolic blood pressure. Follow-up comparison showed lower diastolic pressure during tilt after THC than after placebo in the group without cannabis use. Other measured outcomes did not uniformly show significant interactions.

The authors also described increased dizziness and nausea during tilt in nonregular users. These observations should not be generalized into a demonstrated universal cardiovascular hazard or a precise fall-risk estimate.

Order and measurement limitations matter

The study was single-blind and oral THC administration was not randomized. Treatment order could therefore contribute to differences. The small sample and unusable ECG segments also limited the information available for some analyses.

Blood pressure was not continuously measured beat to beat. The experiment could not fully characterize moment-to-moment hemodynamic changes or establish a detailed baroreflex mechanism. Hydration remained another consideration for future studies.

What a next-morning opinion can say

The result challenges the assumption that a normal resting examination proves recovery of every physiological response. It does not provide a cannabis concentration cutoff, a universal next-morning impairment classification or proof that a particular person’s dizziness was THC-caused.

An individual assessment requires the dose, timing, medicines, hydration, symptoms and relevant clinical testing. Resting stability, orthostatic response and capacity for driving or work should remain separate conclusions.

For context, see our discussion of THC concentrations and the separate question of impairment.

Primary research

Joshua E. Gonzalez and colleagues. Bedtime tetrahydrocannabinol ingestion reduces morning orthostatic cardiovascular reactivity in adults: An exploratory study. Physiological Reports (2026). DOI: 10.14814/phy2.71076.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us